Literature DB >> 32471644

De-isolation of COVID-19-positive hemodialysis patients in the outpatient setting: a single-center experience.

Caroline Dudreuilh1, Nicola Kumar1, Vicki Moxham1, Carolyn Hemsley2, Simon Goldenberg2, Dimitrios-Anestis Moutzouris3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32471644      PMCID: PMC7206422          DOI: 10.1016/j.kint.2020.04.021

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


× No keyword cloud information.
To the editor: The advice for patients presenting with coronavirus disease 2019 (COVID-19) symptoms is to self-isolate for 7 days after the onset of symptoms for the individual case and 14 days for the household. Dialysis patients can be considered as immunocompromised and display a decreased ability to develop seroconversion to infectious diseases. Therefore, 7 to 14 days may not be an appropriate threshold in a dialysis population. In our center, we provide dialysis in 2 hospital-based and 6 satellite units, for a total of 664 patients (see Supplementary Methods). We isolated our COVID-19–positive dialysis outpatients in a dedicated unit and followed a pathway for de-escalation of stable patients with serial COVID-19 swabs, starting 7 days after confirmed diagnosis (Figure 1 , Supplementary Table S1). Thirty-four COVID-19–positive patients who had at least 3 swabs were included: 20 patients were de-isolated in less than 14 days (59%) with 9% on day 9. By day 12, 35% of patients could be dialyzed in their base unit (which is crucial for capacity). However, by day 15, 14 patients (41%) had not cleared the virus and could not be repatriated: 5 patients cleared the virus later (median of 18 days [range, 16–21]) and 9 patients were still positive or had only one negative swab at the end of follow-up. It is unclear whether detection of viral RNA represents the ability to transmit the virus, , but until more evidence is available, it would be prudent to isolate patients as discussed to prevent cross-contamination in this high-risk population.
Figure 1

De-escalation plan for coronavirus disease 2019 (COVID-19)–positive dialysis patients. HD, hemodialysis.

De-escalation plan for coronavirus disease 2019 (COVID-19)–positive dialysis patients. HD, hemodialysis.

Disclosure

SG reports personal fees from Astellas, Enterobiotix, Menarini, MSD, Pfizer, and Shionogi, outside of the submitted work. All the other authors declared no competing interests.
  12 in total

1.  COVID-19 Antibodies and Outcomes among Outpatient Maintenance Hemodialysis Patients.

Authors:  Minesh Khatri; Shahidul Islam; Paula Dutka; John Carson; James Drakakis; Louis Imbriano; Imran Jawaid; Tapan Mehta; Nobuyuki Miyawaki; Elain Wu; Stephen Yang; Nicole Ali; Jasmin Divers; Candace Grant; Naveed Masani
Journal:  Kidney360       Date:  2020-12-09

2.  The Characteristics, Dynamics, and the Risk of Death in COVID-19 Positive Dialysis Patients in London, UK.

Authors:  Dalvir Kular; Irina Chis Ster; Alexander Sarnowski; Eirini Lioudaki; Dandisonba C B Braide-Azikiwe; Martin L Ford; David Makanjuola; Alexandra Rankin; Hugh Cairns; Joyce Popoola; Nicholas Cole; Mysore Phanish; Richard Hull; Pauline A Swift; Debasish Banerjee
Journal:  Kidney360       Date:  2020-09-10

Review 3.  The frail world of haemodialysis patients in the COVID-19 pandemic era: a systematic scoping review.

Authors:  Gaetano Alfano; Annachiara Ferrari; Riccardo Magistroni; Francesco Fontana; Gianni Cappelli; Carlo Basile
Journal:  J Nephrol       Date:  2021-08-21       Impact factor: 3.902

4.  [Protection of nephrology health professionals during the COVID-19 pandemic].

Authors:  María Dolores Arenas; Judit Villar; Cristina González; Higinio Cao; Silvia Collado; Francesc Barbosa; Marta Crespo; Juan Pablo Horcajada; Julio Pascual
Journal:  Nefrologia (Engl Ed)       Date:  2020-07-01

5.  COVID-19 in dialysis patients: adding a few more pieces to the puzzle.

Authors:  T Alp Ikizler
Journal:  Kidney Int       Date:  2020-05-08       Impact factor: 10.612

6.  COVID-19 in a dialysis center in Milan from March to June 2020: understanding how to respond to the second wave of the pandemic.

Authors:  Andrea Galassi; Lorenza Magagnoli; Mario Cozzolino
Journal:  J Nephrol       Date:  2021-02       Impact factor: 4.393

7.  IgG SARS-CoV-2 antibodies persist at least for 10 months in patients on hemodialysis.

Authors:  C Dudreuilh; T Roper; C Breen; P Chowdhury; S Douthwaite; N Kumar; D A Moutzouris
Journal:  Kidney Int Rep       Date:  2021-04-08

8.  Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review.

Authors:  Shoulian Zhou; Jing Xu; Cheng Xue; Bo Yang; Zhiguo Mao; Albert C M Ong
Journal:  Ren Fail       Date:  2020-11-09       Impact factor: 2.606

9.  An Interprofessional Approach in Caring for a Patient on Maintenance Hemodialysis with COVID-19 in Toronto, Canada: An Educational Case Report.

Authors:  Elizabeth M Hendren; Nicola Matthews; Mathew Oliver; Julie Rice; Sheldon W Tobe; Bourne L Auguste
Journal:  Can J Kidney Health Dis       Date:  2020-09-08

10.  From Infection to Immunity - Impact of COVID-19 Across Nine Hemodialysis Centres in Mumbai.

Authors:  Viswanath Billa; Jatin Kothari; Shrirang Bichu; Rajesh Kumar; Deepa Usulumarty; Parag Tilve; Sundaram Hariharan
Journal:  Indian J Nephrol       Date:  2021-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.